Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A comparison of two products for oral nicotine replacement with respect to relief of urges to smoke after single doses of nicotine.
This study compares a new oral Nicotine Replacement Therapy (NRT) product with NiQuitinâ„¢ lozenge 2 mg and 4 mg, respectively, after 5 hours of witnessed nicotine abstinence with respect to urges to smoke during the first 5 minutes after start of treatment. Single doses of each treatment are given during separate treatment visits scheduled in a crossover setting with randomized treatment sequences. The study will include 200 healthy smokers between 19-55 years, who have been smoking at least 10 cigarettes daily during at least one year preceding inclusion, and who smoke within 30 minutes of waking up. Subjects, study personnel and monitor will be aware of what type of product is administered at a given visit, but not of the administered dose of the lozenge.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LHN1548 | Experimental | Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period. |
|
| 2019706 | Active Comparator | Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period. |
|
| 2020005 | Active Comparator | Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nicotine | Drug | Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period |
|
| Measure | Description | Time Frame |
|---|---|---|
| Areas under the linearly interpolated urges to smoke vs. time curve evaluated in a hierarchical order starting with the 5 minutes' evaluation (AUC5min, AUC3min, AUC1min) | from time zero following 5 hours of smoking abstinence (baseline), until 5 minutes, until 3 minutes, and until 1 minute, respectively |
| Measure | Description | Time Frame |
|---|---|---|
| Areas under the linearly interpolated urges to smoke vs. time curve (AUC10min) | from time zero following 5 hours of smoking abstinence (baseline), until 10 minutes thereafter | |
| Time to a 25%, 50%, 75%, and 90% reduction from baseline intensity of urges to smoke score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Elisabeth Kruse, PhD | McNeil AB | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Pharmacology | Lund | 222 20 | Sweden |
Not provided
| ID | Term |
|---|---|
| D016540 | Smoking Cessation |
| ID | Term |
|---|---|
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D009538 | Nicotine |
| ID | Term |
|---|---|
| D012991 | Solanaceous Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D011725 | Pyridines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Nicotine | Drug | Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period. |
|
|
| Nicotine | Drug | Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period. |
|
|
| from time zero following 5 hours of smoking abstinence (baseline), until 2 hours thereafter |
| Proportion of subjects reaching 25%, 50%, 75% and 90% reduction of urges to smoke | from time zero following 5 hours of smoking abstinence (baseline), until 2 hours thereafter |
| Study treatment acceptability, evaluated using pair-wise treatment comparisons of ordered categorical-scale assessments | At the end of three separate visits, at least 36 hours apart |
| D006573 |
| Heterocyclic Compounds, 1-Ring |